G6PD作为胶质瘤风险、预后和化疗敏感性的预测标志物
该回顾性13年队列研究利用台湾国民健康保险研究数据库分析癌症风险(4066例G6PD缺乏患者和16264例对照),并从TCGA下载Ⅱ-Ⅲ级胶质瘤(LGG,n=515)和胶质母细胞瘤(GBM,n=155)的RNAseq及临床数据分析。结果显示G6PD缺乏患者癌症风险增加,尤其脑肿瘤(调整HR 10.5,95%CI 1.03-7.60);肿瘤G6PD高表达与LGG患者生存差相关,但在GBM中不相关;基于G6PD及9个相关基因的表达模型可独立预测LGG患者生存。
要点
- G6PD缺乏患者癌症风险增加,尤其脑肿瘤(调整HR 10.5,95%CI 1.03-7.60)。
- 肿瘤G6PD高表达与LGG患者生存差相关,但在GBM中不相关。
- G6PD及9个相关基因的表达模型可独立预测LGG患者生存。
核心结论
- 本研究提示G6PD可能是预测胶质瘤风险、预后和化疗敏感性的标志物。
研究设计与样本
- 回顾性13年队列研究,利用台湾国民健康保险研究数据库分析癌症风险(4066例G6PD缺乏患者和16264例对照)。
- 从TCGA下载Ⅱ-Ⅲ级胶质瘤(LGG,n=515)和胶质母细胞瘤(GBM,n=155)的RNAseq及临床数据进行分析。
- 应用生物信息学方法构建胶质瘤预后模型并基于肿瘤G6PD相关基因表达预测化疗反应。
- 预测结果在另一胶质瘤队列GSE 16011和KALS1细胞系中进行验证。
主要发现
- G6PD缺乏患者癌症风险增加,尤其脑肿瘤(调整HR 10.5,95%CI 1.03-7.60)。
- 肿瘤G6PD高表达与LGG患者生存差相关,但在GBM中不相关。
- 基于G6PD及9个相关基因(PSMA2、PSMB8、SHFM1、GSS、GSTK1、MGST2、POLD3、MSH2、MSH6)表达水平的预后模型可独立预测LGG患者生存。
- 对213个癌细胞系数据库的提升决策树分析显示G6PD表达对吉西他滨和硼替佐米反应具有预测价值。
- 在KALS1细胞系中敲低G6PD增强了对这两种化疗药物的敏感性。
关键数值与推荐
- G6PD缺乏患者脑肿瘤风险调整HR 10.5(95%CI 1.03-7.60)。
- 预后模型使用G6PD及9个相关基因(PSMA2、PSMB8、SHFM1、GSS、GSTK1、MGST2、POLD3、MSH2、MSH6)的表达水平。
- 癌细胞系数据库包含213个癌细胞系。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme preventing cells from oxidative damage and has been reported to have tumor-promoting roles. This study aims to comprehensively evaluate the predictive values of G6PD on brain tumor risk, prognosis and chemo-resistance. METHODS: A retrospective 13-year cohort study analyzing cancer risk using the Taiwan National Health Insurance Research Database (4066 G6PD deficiency patients and 16,264 controls) was conducted. Furthermore, RNAseq and clinical data of grade II-III glioma (LGG, n = 515) and glioblastoma (GBM, n = 155) were downloaded from The Cancer Genome Atlas (TCGA) and analyzed. Bioinformatics methods were applied to build a glioma prognostication model and to predict response to chemotherapy based on tumor G6PD-related gene expressions. The predicted results were validated in another glioma cohort GSE 16011 and in KALS1 cell line. RESULTS: G6PD-dificient patients were found to have an increased risk for cancers, especially for brain tumor (adjusted hazard ratio (HR) 10.5, 95% CI 1.03-7.60). Furthermore, higher tumor G6PD expression was associated with poor patient survival in LGG, but not in GBM. A prognostication model using expression levels of G6PD and 9 related genes (PSMA2, PSMB8, SHFM1, GSS, GSTK1, MGST2, POLD3, MSH2, MSH6) could independently predict LGG patient survival. Boosted decision tree analysis on 213 cancer cell line database revealed predictive values of G6PD expression on response to gemcitabine and bortezomib. Knockdown of G6PD in KALS1 cell line enhanced its sensitivity to both chemotherapeutic agents. CONCLUSIONS: Our study suggests that G6PD could be a marker predicting glioma risk, prognosis and chemo-sensitivity.
引用
- Yang CA, Huang HY, Lin CL, et al. G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity. J Neurooncol. 2018. PMID: 29845423. doi:10.1007/s11060-018-2911-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。